- Home
- DSGN vs MACI Comparison
DSGN vs MACI Comparison
Compare DSGN & MACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- MACI
- Stock Information
- Founded
- DSGN 2017
- MACI 2024
- Country
- DSGN United States
- MACI United States
- Employees
- DSGN N/A
- MACI N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- MACI
- Sector
- DSGN Health Care
- MACI
- Exchange
- DSGN Nasdaq
- MACI NYSE
- Market Cap
- DSGN 264.4M
- MACI 215.8M
- IPO Year
- DSGN 2021
- MACI 2024
- Fundamental
- Price
- DSGN $5.57
- MACI $10.05
- Analyst Decision
- DSGN Hold
- MACI
- Analyst Count
- DSGN 3
- MACI 0
- Target Price
- DSGN $7.00
- MACI N/A
- AVG Volume (30 Days)
- DSGN 142.1K
- MACI 24.3K
- Earning Date
- DSGN 11-07-2024
- MACI 01-01-0001
- Dividend Yield
- DSGN N/A
- MACI N/A
- EPS Growth
- DSGN N/A
- MACI N/A
- EPS
- DSGN N/A
- MACI N/A
- Revenue
- DSGN N/A
- MACI N/A
- Revenue This Year
- DSGN N/A
- MACI N/A
- Revenue Next Year
- DSGN N/A
- MACI N/A
- P/E Ratio
- DSGN N/A
- MACI N/A
- Revenue Growth
- DSGN N/A
- MACI N/A
- 52 Week Low
- DSGN $2.13
- MACI $9.95
- 52 Week High
- DSGN $7.77
- MACI $10.05
- Technical
- Relative Strength Index (RSI)
- DSGN 47.80
- MACI N/A
- Support Level
- DSGN $5.32
- MACI N/A
- Resistance Level
- DSGN $7.77
- MACI N/A
- Average True Range (ATR)
- DSGN 0.58
- MACI 0.00
- MACD
- DSGN -0.09
- MACI 0.00
- Stochastic Oscillator
- DSGN 19.12
- MACI 0.00
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About MACI MELAR ACQUISITION CORP. I
Melar Acquisition Corp I is a blank check company.